Trial · NCT02160145
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up. | Tolvaptan | -2.339 | Standard Error 0.240 | mL/min/1.73 m^2/year | |
| The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up. | Placebo | -3.610 | Standard Error 0.240 | mL/min/1.73 m^2/year | |
| Mean Annualized Slope of eGFR Change | Tolvaptan | -3.160 | Standard Error 0.140 | mL/min/1.73m^2/year | |
| Mean Annualized Slope of eGFR Change | Placebo | -4.170 | Standard Error 0.142 | mL/min/1.73m^2/year | |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month 3 | 10.2 | Standard Deviation 80.3 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month 3 | 177.7 | Standard Deviation 124.5 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month 6 | 22.9 | Standard Deviation 84.3 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month 6 | 179.1 | Standard Deviation 126.2 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month 9 | 30.4 | Standard Deviation 92.1 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month 9 | 179.9 | Standard Deviation 125.1 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month12 | 36.9 | Standard Deviation 96.0 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month12 | 180.3 | Standard Deviation 121.1 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Follow-up | 162.4 | Standard Deviation 114.0 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Follow-up | 179.5 | Standard Deviation 128.9 | milliosmole per kilogram (mOSm/kg) |
| Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month 3 | 0.0001 | Standard Deviation 0.0022 | unitless |
| Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month 3 | 0.0041 | Standard Deviation 0.0033 | unitless |
| Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month 6 | 0.0003 | Standard Deviation 0.0024 | unitless |
| Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month 6 | 0.0042 | Standard Deviation 0.0033 | unitless |
| Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up | Tolvaptan | Month 9 | 0.004 | Standard Deviation 0.0025 | unitless |
| Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up | Placebo | Month 9 | 0.0040 | Standard Deviation 0.0032 | unitless |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02160145/results